Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults by Wiffen, Philip J. et al.
Wiffen, Philip J. and Knaggs, Roger and Derry, Sheena 
and Cole, Peter and Phillips, Tudor and Moore, R. 
Andrew (2016) Paracetamol (acetaminophen) with or 
without codeine or dihydrocodeine for neuropathic pain 
in adults. Cochrane Database of Systematic Reviews 
(12). CD012227/1-CD012227/23. ISSN 1469-493X 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/49233/1/Paracetamol_NeuP.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the University of Nottingham End User licence and may 
be reused according to the conditions of the licence.  For more details see: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
Cochrane Database of Systematic Reviews
Paracetamol (acetaminophen) with or without codeine or
dihydrocodeine for neuropathic pain in adults (Review)
Wiffen PJ, Knaggs R, Derry S, Cole P, Phillips T, Moore RA
Wiffen PJ, Knaggs R, Derry S, Cole P, Phillips T, Moore RA.
Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults.
Cochrane Database of Systematic Reviews 2016, Issue 12. Art. No.: CD012227.
DOI: 10.1002/14651858.CD012227.pub2.
www.cochranelibrary.com
Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
5BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
13DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
23INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iParacetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Paracetamol (acetaminophen) with or without codeine or
dihydrocodeine for neuropathic pain in adults
Philip J Wiffen1, Roger Knaggs2 , Sheena Derry1, Peter Cole3, Tudor Phillips1, R Andrew Moore1
1Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics), University of Oxford, Oxford,
UK. 2School of Pharmacy, University of Nottingham, Nottingham, UK. 3Oxford Pain Relief Unit, Churchill Hospital, Oxford
University Hospitals NHS Trust, Oxford, UK
Contact address: R AndrewMoore, Pain Research and NuffieldDepartment of Clinical Neurosciences (Nuffield Division of Anaesthet-
ics), University ofOxford, PainResearchUnit, Churchill Hospital, Oxford,Oxfordshire,OX37LE,UK. andrew.moore@ndcn.ox.ac.uk.
Editorial group: Cochrane Pain, Palliative and Supportive Care Group.
Publication status and date: Edited (no change to conclusions), published in Issue 1, 2017.
Citation: Wiffen PJ, Knaggs R, Derry S, Cole P, Phillips T, Moore RA. Paracetamol (acetaminophen) with or without codeine or
dihydrocodeine for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2016, Issue 12. Art. No.: CD012227. DOI:
10.1002/14651858.CD012227.pub2.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Paracetamol, either alone or in combination with codeine or dihydrocodeine, is commonly used to treat chronic neuropathic pain.
This review sought evidence for efficacy and harm from randomised double-blind studies.
Objectives
To assess the analgesic efficacy and adverse events of paracetamol with or without codeine or dihydrocodeine for chronic neuropathic
pain in adults.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase from inception to July 2016,
together with reference lists of retrieved papers and reviews, and two online study registries.
Selection criteria
We included randomised, double-blind studies of two weeks’ duration or longer, comparing paracetamol, alone or in combination with
codeine or dihydrocodeine, with placebo or another active treatment in chronic neuropathic pain.
Data collection and analysis
Two review authors independently searched for studies, extracted efficacy and adverse event data, and examined issues of study quality
and potential bias. We did not carry out any pooled analyses. We assessed the quality of the evidence using GRADE.
Main results
No study satisfied the inclusion criteria. Effects of interventions were not assessed as there were no included studies. We have only very
low quality evidence and have no reliable indication of the likely effect.
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Authors’ conclusions
There is insufficient evidence to support or refute the suggestion that paracetamol alone, or in combination with codeine or dihy-
drocodeine, works in any neuropathic pain condition.
P L A I N L A N G U A G E S U M M A R Y
Paracetamol (acetaminophen) alone, or in combination with codeine or dihydrocodeine, for neuropathic pain in adults
Bottom line
There is no good evidence to support or refute the suggestion that paracetamol alone, or in combinationwith codeine or dihydrocodeine,
works in any neuropathic pain condition.
Background
Neuropathic pain is pain coming from damaged nerves. It is different from pain messages that are carried along healthy nerves from
damaged tissue (e.g. a fall or cut, or arthritic knee). Neuropathic pain is often treated by different medicines (drugs) to those used for
pain from damaged tissue, which we often think of as painkillers. Medicines that are sometimes used to treat depression or epilepsy
(fits) can be very effective in some people with neuropathic pain. But sometimes paracetamol is used to treat neuropathic pain, either
by itself or with the opioid painkillers codeine or dihydrocodeine.
Paracetamol has been widely available for over 50 years. There is evidence it works as a painkiller in some short-lived pains, but it does
not appear to work well for long lasting pains. We do not really know how it works. Paracetamol is commonly used combined with
opioid drugs.
Opioid painkillers are drugs like morphine. Morphine is derived from plants, but many opioids are also made in a laboratory rather
than being extracted from plants. Codeine and dihydrocodeine are often combined with paracetamol.
Study characteristics
In July 2016, we searched for clinical trials where paracetamol alone, or in combination with codeine or dihydrocodeine, was used to
treat neuropathic pain in adults. We found no studies that met our requirements for the review.
Key results
Because there were no studies that could answer the questions in a reliable way, we cannot say whether paracetamol alone, or in
combination with codeine or dihydrocodeine, works for chronic neuropathic pain.
Quality of the evidence
We rated the quality of the evidence as very low because there were no studies. Very low quality evidencemeans that we are very uncertain
about the impact of paracetamol alone, or in combination with codeine or dihydrocodeine, in any neuropathic pain condition.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Paracetamol alone, paracetamol plus codeine, or paracetamol plus dihydrocodeine compared with placebo for neuropathic pain
Patient or population: adults with chronic neuropathic pain
Settings: community
Intervention: paracetamol alone, paracetamol plus codeine, or paracetamol plus dihydrocodeine
Comparison: placebo
Outcomes Probable outcome with
intervention
Probable outcome with
comparator
RR
(95% CI)
No of studies, participants Certainty of the evidence
(GRADE)
Comments
Moderate benef it :
At least 30% reduct ion
in pain, or
PGIC much or very
much improved
No data No data Not
calculated
No data Very low No trials found for parac-
etamol alone, paracetamol
plus codeine, or paraceta-
mol plus dihydrocodeine
Substant ial benef it :
At least 50% reduct ion
in pain, or
PGIC much improved
No data No data Not
calculated
No data Very low No trials found for parac-
etamol alone, paracetamol
plus codeine, or paraceta-
mol plus dihydrocodeine
Lack of ef f icacy with-
drawal
No data No data Not
calculated
No data Very low No trials found for parac-
etamol alone, paracetamol
plus codeine, or paraceta-
mol plus dihydrocodeine
Adverse event with-
drawal
No data No data Not
calculated
No data Very low No trials found for parac-
etamol alone, paracetamol
plus codeine, or paraceta-
mol plus dihydrocodeine
Serious adverse events No data No data Not
calculated
No data Very low No trials found for parac-
etamol alone, paracetamol
plus codeine, or paraceta-
mol plus dihydrocodeine
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Deaths No data No data Not
calculated
No data Very low No trials found for parac-
etamol alone, paracetamol
plus codeine, or paraceta-
mol plus dihydrocodeine
CI: conf idence interval; PGIC: Patient Global Impression of Change; RR: risk rat io
Descriptors for levels of evidence (EPOC 2015):
High quality: This research provides a very good indicat ion of the likely ef fect. The likelihood that the ef fect will be substant ially dif f erent† is low.
M oderate quality: This research provides a good indicat ion of the likely ef fect. The likelihood that the ef fect will be substant ially dif f erent† is moderate.
Low quality: This research provides some indicat ion of the likely ef fect. However, the likelihood that it will be substant ially dif f erent† is high.
Very low quality: This research does not provide a reliable indicat ion of the likely ef fect. The likelihood that the ef fect will be substant ially dif f erent† is very high.
† Substant ially dif f erent: a large enough dif ference that it m ight af fect a decision
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B A C K G R O U N D
This review is based on a template for reviews of drugs used to
relieve neuropathic pain. The aim is for all reviews to use the
same methods, based on new criteria for what constitutes reliable
evidence in chronic pain (Moore 2010a; Moore 2012; Appendix
1).
Description of the condition
The 2011 International Association for the Study of Pain defini-
tion of neuropathic pain is “pain caused by a lesion or disease of the
somatosensory system” (Jensen 2011), and based on a definition
agreed at an earlier consensusmeeting (Treede 2008).Neuropathic
pain is a consequence of a pathological maladaptive response of
the nervous system to ’damage’ from a wide variety of potential
causes. It is characterised by pain in the absence of a noxious stim-
ulus and may be spontaneous (continuous or paroxysmal) in its
temporal characteristics or be evoked by sensory stimuli (dynamic
mechanical allodynia where pain is evoked by light touch of the
skin). Neuropathic pain is associated with a variety of sensory loss
(numbness) and sensory gain (allodynia) clinical phenomena, the
exact pattern of which vary between people and disease, perhaps
reflecting different pain mechanisms operating in an individual
person and, therefore, potentially predictive of response to treat-
ment (Demant 2014; Helfert 2015; von Hehn 2012). Preclinical
research hypothesises a bewildering array of possible pain mech-
anisms that may operate in people with neuropathic pain, which
largely reflect pathophysiological responses in both the central and
peripheral nervous systems, including neuronal interactions with
immune cells (Baron 2012; Calvo 2012; vonHehn2012).Overall,
the treatment gains in neuropathic pain, to even themost effective
of available drugs, are modest (Finnerup 2015; Moore 2013a),
and a robust classification of neuropathic pain is not yet available
(Finnerup 2013).
Neuropathic pain is usually divided according to the cause of
nerve injury. Theremay bemany causes, but some common causes
of neuropathic pain include diabetes (painful diabetic neuropa-
thy (PDN)), shingles (postherpetic neuralgia (PHN)), amputation
(stump and phantom limb pain), neuropathic pain after surgery
or trauma, stroke or spinal cord injury, trigeminal neuralgia, and
HIV infection. Sometimes the cause is unknown.
Many people with neuropathic pain conditions are significantly
disabled with moderate or severe pain for many years. Chronic
pain conditions comprised five of the 11 top-ranking conditions
for years lived with disability in 2010 (Vos 2012), and are respon-
sible for considerable loss of quality of life and employment, and
increased healthcare costs (Moore 2014a).
In systematic reviews, the overall prevalence of neuropathic pain
in the general population is reported to be between 7% and 10%
(van Hecke 2014), and about 7% in a systematic review of stud-
ies published since 2000 (Moore 2014a). In individual countries,
prevalence rates have been reported as 3.3% in Austria (Gustorff
2008), 6.9% in France (Bouhassira 2008), and up to 8% in the
UK (Torrance 2006). Some forms of neuropathic pain are increas-
ing, particularly PDN and postsurgical chronic pain (which is of-
ten neuropathic in origin) (Hall 2008). The prevalence of PHN
is likely to fall if vaccination against the herpes virus becomes
widespread.
Estimates of incidence vary between individual studies for partic-
ular origins of neuropathic pain, often because of small numbers
of cases. In primary care in the UK, between 2002 and 2005, the
incidences (per 100,000 person-years’ observation) were 28 (95%
confidence interval (CI) 27 to 30) for PHN, 27 (95% CI 26 to
29) for trigeminal neuralgia, 0.8 (95% CI 0.6 to 1.1) for phan-
tom limb pain, and 21 (95% CI 20 to 22) for PDN (Hall 2008).
Other studies have estimated an incidence of 4 in 100,000 per
year for trigeminal neuralgia (Katusic 1991; Rappaport 1994), and
12.6 per 100,000 person-years for trigeminal neuralgia and 3.9
per 100,000 person-years for PHN in a study of facial pain in the
Netherlands (Koopman 2009). One systematic review of chronic
pain demonstrated that some neuropathic pain conditions, such
as PDN, can be more common than other neuropathic pain con-
ditions, with prevalence rates up to 400 per 100,000 person-years
(McQuay 2007).
Neuropathic pain is difficult to treat effectively, with only a mi-
nority of people experiencing a clinically relevant benefit from
any one intervention. A multidisciplinary approach is now advo-
cated, combining pharmacological interventions with physical or
cognitive (or both) interventions. Conventional analgesics such as
paracetamol and nonsteroidal anti-inflammatory drugs (NSAID)
are not thought to be effective, but without evidence to support
or refute that view. Some people may derive some benefit from
a topical lidocaine patch or low-concentration topical capsaicin,
although evidence about benefits is uncertain (Derry 2012; Derry
2014). High-concentration topical capsaicin may benefit some
people with PHN (Derry 2013a). Treatment is often by so-called
’unconventional analgesics’ (pain modulators) such as antidepres-
sants (duloxetine and amitriptyline; Lunn 2014; Moore 2014b;
Moore 2015; Sultan 2008), or antiepileptic drugs (gabapentin or
pregabalin; Moore 2009; Moore 2014c; Wiffen 2013).
The proportion of people who achieve worthwhile pain relief (typ-
ically at least 50%pain intensity reduction;Moore 2013b) is small,
generally only 10% to 25% more than with placebo, with num-
bers needed to treat for an additional beneficial outcome (NNT)
usually between 4 and 10 (Kalso 2013; Moore 2013a). Neuro-
pathic pain is not particularly different from other chronic pain
conditions in that only a small proportion of trial participants have
a good response to treatment (Moore 2013a).
The current National Institute for Health and Care Excellence
(NICE) guidance for the pharmacological management of neuro-
pathic pain suggests offering a choice of amitriptyline, duloxetine,
gabapentin, or pregabalin as initial treatment for neuropathic pain
(except for trigeminal neuralgia), with switching if the first, sec-
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ond, or third drugs tried are not effective or not tolerated (NICE
2013). This concurs with other recent guidance (Finnerup 2015).
Description of the intervention
Paracetamol (acetaminophen) is available in a very large number of
formats and products with different names, including Panadol and
Tylenol. Paracetamol plus codeine often comes with the generic
name co-codamol, and paracetamol plus dihydrocodeine as co-
dydramol. A listing of brand names by country is available but the
list is too long to be given here (Drugs.com 2016). Paracetamol
use is measured in thousands of tonnes, and questions have been
asked about the benefits and risk of such extensive use (Moore
2016).
Paracetamol was first identified as the active metabolite of two
older antipyretic drugs, acetanilide and phenacetin, in the late
nineteenth century (Axelrod 2003). Since then it has become one
of themost popular antipyretic and analgesic drugsworldwide, and
is often also used in combinationwith other drugs. It became avail-
able in the UK on prescription in 1956, and without prescription
(over-the-counter) in 1963 (PIC 2015). Nonprescription medica-
tions are less expensive, more accessible, and have favourable safety
profiles relative to many prescription treatments.
Despite a low incidence of adverse effects, paracetamol has a recog-
nised potential for hepatotoxicity and is thought to be responsi-
ble for approximately half of all cases of liver failure in the UK
(Hawton 2001), and about 40% in the US (Norris 2008). One
study evaluating all cases of acute liver failure leading to registra-
tion for transplantation (ALFT) across seven European countries
for a three-year period showed that paracetamol overdose was re-
sponsible for one sixth of cases of ALFT, though this varied con-
siderably between each country (Gulmez 2015). Acute paraceta-
mol hepatotoxicity at therapeutic doses has been judged to be ex-
tremely unlikely, despite reports of so-called ’therapeutic misad-
venture’ (Prescott 2000). However, it has been observed that non-
overdose ALFT is more likely to follow therapeutic-dose paraceta-
mol exposure than similar NSAID exposure (Gulmez 2013). Leg-
islative changes have been introduced in the UK to restrict pack
sizes and the maximum number of tablets permitted in nonpre-
scription sales (CSM 1997) on the basis of evidence that poison-
ing is lower in countries that restrict availability (Gunnell 1997;
Hawton 2001). The contribution of these changes, which were
inconvenient and costly (particularly to people with chronic pain),
to any observed reductions in incidence of liver failure or death,
remains uncertain (Bateman 2014a; Bateman 2014b; Hawkins
2007; Hawton 2013). There have been concerns over the safety of
paracetamol in people with compromised hepatic function (peo-
ple with severe alcoholism, cirrhosis, or hepatitis), but these have
not been substantiated (Dart 2000; PIC 2015).
The use of paracetamol during pregnancy has been questioned
following reports that it is linked to behavioural problems and
hyperkinetic disorders in children whose mothers took it during
pregnancy (Liew 2014), and suggestions that it can interfere with
sex hormones (Mazaud-Guittot 2013).
In an analysis of single dose studies in migraine, there was no
evidence that adverse events weremore commonwith paracetamol
1000mg thanwith placebo, andno serious adverse events occurred
with paracetamol alone (Derry 2013b).
Oral paracetamol has long been used as a first-line analgesic for
a variety of acute and chronic conditions. It has modest efficacy
in acute pain and migraine (Derry 2013b; Toms 2008), although
some randomised trials, systematic reviews, and meta-analyses
have suggested that there is no good evidence for a clinically rel-
evant benefit of paracetamol (as monotherapy) in many chronic
pain conditions such as osteoarthritis and back pain (Machado
2015;Moore 2014d;Williams 2014). There are few or no data for
a range of other common painful conditions, including dysmenor-
rhoea and neck pain. Moreover, accumulating evidence from ob-
servational studies indicates a considerable degree of paracetamol
toxicity, especially at the upper end of standard analgesic doses
(Roberts 2016).
Oral paracetamol in fixed-dose combination with codeine or dihy-
drocodeine are frequently used in treating people with neuropathic
pain (Hall 2013). There is good evidence showing that paraceta-
mol plus codeine combinations are effective in acute pain (Toms
2009), but limited evidence for cancer pain (Straube 2014). Dihy-
drocodeine was not effective in acute postoperative pain (Moore
2000), and there is very little evidence on its efficacy in other
pain conditions. Codeine is not effective in acute postoperative
pain (Derry 2010). There is current uncertainty about the effi-
cacy of opioids in chronic noncancer pain because of the influence
of imputation methods where there are high levels of participant
withdrawals in trials, and also in clinical practice. Reviews of oxy-
codone and buprenorphine for neuropathic pain have found no
evidence of efficacy (Gaskell 2014; Wiffen 2015).
How the intervention might work
Paracetamol
The lack of significant anti-inflammatory activity of paracetamol
implies a mode of action distinct from that of NSAIDs; yet, de-
spite years of use and research, the mechanisms of action of parac-
etamol are not fully understood. NSAIDs act by inhibiting the ac-
tivity of cyclo-oxygenase (COX), now recognised to consist of two
isoforms (COX-1 and COX-2), which catalyses the production of
prostaglandins responsible for pain and inflammation. Paraceta-
mol has previously been shown to have no significant effects on
COX-1 or COX-2 (Schwab 2003), but is now being considered
as a selective COX-2 inhibitor (Hinz 2008). Significant parac-
etamol-induced inhibition of prostaglandin production has been
demonstrated in tissues in the brain, spleen, and lung (Botting
2000; Flower 1972). A ’COX-3 hypothesis’, wherein the efficacy
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of paracetamol is attributed to its specific inhibition of a third
COX isoform enzyme, COX-3 (Botting 2000; Chandrasekharan
2002), now has little credibility, and a central mode action of
paracetamol is thought to be likely (Graham 2005). Paracetamol
metabolism is subject to genetic variation (Zhao 2011).
There is some experimental research in rats to suggest that parac-
etamol may have an effect in neuropathic pain via cannabinoid
receptors (Curros-Criado 2009; Dani 2007). One single case re-
port suggested intravenous paracetamol was effective for phantom
limb pain (Gulcu 2007).
Codeine and dihydrocodeine
Codeine and dihydrocodeine are opioids.
The analgesic effects of codeine are attributed to its metabolism
in the liver to the active compounds morphine and morphine-
6-glucuronide. Normally between 5% and 10% is converted to
morphine, and a dose of codeine phosphate of about 30 mg is
considered equivalent to morphine 3 mg. However, the capacity
to metabolise codeine to its active metabolites varies between peo-
ple, with up to 10% of white people, 2% of Asian people, and
1% of Arabic people being ’poor metabolisers’. In these people,
codeine is a relatively ineffective analgesic. The enzyme CYP2D6
is a member of the cytochrome P450 mixed-function oxidase sys-
tem enzymes, and one of the most important enzymes involved in
themetabolism of xenobiotics in the body. Due to genetic variabil-
ity in the CYP2D6 enzyme, up to 40% of people in some societies
are ’ultra-metabolisers’ and are able to convert more of the codeine
to morphine, putting them at increased risk of toxicity from stan-
dard doses (Sistonen 2007). Various medications interfere with
the enzymes that catalyse the metabolism of codeine, increasing or
decreasing the extent of conversion and hence the analgesic effect.
For example, the selective serotonin reuptake inhibitors fluoxetine
and paroxetine reduce conversion, while rifampicin and dexam-
ethasone increase it. The US and Canada issued warnings about
the potentially life-threatening adverse effects in infants of breast-
feedingmothers taking codeine, in 2007 (US) and 2008 (Canada),
and this has led to reductions in codeine use in the postpartum
period (Smolina 2015).
Dihydrocodeine is a synthetic opioid analgesic developed in the
early 1900s. Its structure and pharmacokinetics are similar to that
of codeine (Rowell 1983), and it has been infrequently used for
the treatment of postoperative pain or as an antitussive. Dihy-
drocodeine analgesia seemsnot to be linked tometabolism through
CYP2D6 activity, because the parent compound has analgesic ef-
fects, there are multiple metabolic pathways, and there is a limited
role of dihydromorphine (Leppert 2016).
Why it is important to do this review
Paracetamol, alone or in fixed dose combination with codeine or
dihydrocodeine, was one of the most commonly used first-line
treatments for neuropathic pain conditions such as PHN (27%
of patients), PDN (17%), neuropathic low back pain (37%), or
even phantom limb pain (13%) (Hall 2013). We found no pre-
vious review of paracetamol or paracetamol in combination with
opioids for treating neuropathic pain. Paracetamol combined with
an opioid is considered a reasonable treatment for breakthrough
pain occurring with neuropathic pain treatment in one Canadian
guideline (Moulin 2014), but it is not suggested as a treatment in
other guidelines (NICE 2013) or reviews (Finnerup 2015).
The standards used to assess evidence in chronic pain trials have
changed substantially in recent years, with particular attention be-
ing paid to trial duration, withdrawals, and statistical imputation
following withdrawal, all of which can substantially alter estimates
of efficacy. The most important change is the move from using
mean pain scores, or mean change in pain scores, to the number
of people who have a large decrease in pain (by at least 50%) and
who continue in treatment, ideally in trials of 8 to 12 weeks’ dura-
tion or longer. Pain intensity reduction of 50% or more correlates
with improvements in comorbid symptoms, function, and quality
of life generally (Moore 2013a), and in people with neuropathic
pain (Hoffman 2010). These standards are set out in the PaPaS
Author and Referee Guidance for pain studies of the Cochrane Pain,
Palliative and Supportive Care Group (PaPaS 2012).
This Cochrane review assessed evidence using methods that make
both statistical and clinical sense, using developing criteria for
what constitutes reliable evidence in chronic pain (Moore 2010a).
Trials included and analysed must have met a minimum of report-
ing quality (blinding, randomisation), validity (duration, dose and
timing, diagnosis, outcomes, etc.), and size. Ideally at least 500
participants are needed in a comparison in which the NNT is 4 or
above to measure the magnitude of a treatment effect adequately
(Moore 1998). This approach sets high standards for the demon-
stration of efficacy and marks a departure from how reviews were
conducted previously.
O B J E C T I V E S
To assess the analgesic efficacy and adverse events of paracetamol
with or without codeine or dihydrocodeine for chronic neuro-
pathic pain in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We planned to include randomised controlled trials (RCTs) with
double-blind assessment of participant outcomes following two
weeks or more of treatment, although the emphasis of the review
was on studies with a duration of eight weeks or longer. We re-
quired full journal publication, except for online clinical trial re-
sults summaries of otherwise unpublished clinical trials and ab-
stracts with sufficient data for analysis.We excluded short abstracts
(usually meeting reports). We excluded studies that were nonran-
domised, studies of experimental pain, case reports, and clinical
observations.
Types of participants
Studies included adults aged 18 years and above with one or more
chronic neuropathic pain condition including (but not limited
to):
1. cancer-related neuropathy;
2. central neuropathic pain;
3. complex regional pain syndrome (CRPS) Type II;
4. HIV neuropathy;
5. painful diabetic neuropathy (PDN);
6. phantom limb pain;
7. postherpetic neuralgia (PHN);
8. postoperative or traumatic neuropathic pain;
9. spinal cord injury;
10. trigeminal neuralgia.
We planned to analyse included studies of participants with more
than one type of neuropathic pain according to the primary con-
dition.
Types of interventions
Oral paracetamol with or without codeine or dihydrocodeine, at
any dose, administered for the relief of neuropathic pain and com-
pared with placebo or any active comparator.
Types of outcome measures
We anticipated that studies would use a variety of outcome mea-
sures, with most studies using standard subjective scales (numeri-
cal rating scale or visual analogue scale) for pain intensity or pain
relief, or both. We were particularly interested in Initiative on
Methods, Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) definitions for moderate and substantial benefit in
chronic pain studies (Dworkin 2008). These are defined as:
1. at least 30% pain relief over baseline (moderate);
2. at least 50% pain relief over baseline (substantial);
3. much or very much improved on Patient Global Impression
of Change scale (PGIC; moderate);
4. very much improved on PGIC (substantial).
These outcomes are different from those used in most earlier re-
views, concentrating as they do on dichotomous outcomes where
pain responses do not follow a normal (Gaussian) distribution.
People with chronic pain desire high levels of pain relief, ideally
more than 50% pain intensity reduction, and ideally having no
worse than mild pain (Moore 2013a; O’Brien 2010).
Primary outcomes
1. Participant-reported pain relief of 30% or greater.
2. Participant-reported pain relief of 50% or greater.
3. PGIC much or very much improved.
4. PGIC very much improved.
Secondary outcomes
1. Any pain-related outcome indicating some improvement.
2. Withdrawals due to lack of efficacy, adverse events, and for
any cause.
3. Participants experiencing any adverse event.
4. Participants experiencing any serious adverse event. Serious
adverse events typically include any untoward medical
occurrence or effect that at any dose results in death, is life-
threatening, requires hospitalisation or prolongation of existing
hospitalisation, results in persistent or significant disability or
incapacity, is a congenital anomaly or birth defect, is an
’important medical event’ that may jeopardise the patient, or
may require an intervention to prevent one of the above
characteristics or consequences.
5. Specific adverse events, particularly somnolence and
dizziness.
Search methods for identification of studies
Electronic searches
We searched the following databases, without language restric-
tions:
1. Cochrane Central Register of Controlled Trials
(CENTRAL; via CRSO) on 7 July 2016;
2. MEDLINE (via Ovid) from 1946 to 7 July 2016;
3. Embase (via Ovid) from 1974 to 7 July 2016;
4. Oxford Pain Relief Database (Jadad 1996a).
The search strategies for CENTRAL, MEDLINE, and Embase
are in Appendix 3, Appendix 4, and Appendix 5, respectively.
Searching other resources
We reviewed the bibliographies of any RCTs identified and review
articles, and searched clinical trial databases (ClinicalTrials.gov and
World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) (apps.who.int/trialsearch/)) to iden-
tify additional published or unpublished data (to 7 June 2016).
We did not plan to contact investigators or study sponsors.
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Data collection and analysis
We planned to perform separate analyses according to particular
neuropathic pain conditions. We planned to combine different
neuropathic pain conditions in analyses for exploratory purposes
only.
We planned to perform analyses separately for paracetamol alone,
paracetamol plus codeine, and paracetamol plus dihydrocodeine
according to daily dose of drug used.
Selection of studies
We determined eligibility by reading the abstract of each study
identified by the search.We eliminated studies that clearly did not
satisfy the inclusion criteria, and we obtained full copies of the
remaining studies for further consideration. Two review authors
(RAMand SD) read studies independently and reached agreement
by discussion.Wedidnot anonymise the studies before assessment.
We have provided a PRISMA flow chart.
Data extraction and management
Two review authors (RAM, SD) planned to extract data indepen-
dently using a standard form and check for agreement before en-
try into Review Manager 5 (RevMan 2014), or any other analysis
tool. We resolved disagreements by discussion, involving a third
review author (PW), if necessary. We planned to include informa-
tion about the pain condition and number of participants treated,
drug and dosing regimen, study design (placebo or active control),
study duration and follow-up, analgesic outcome measures and
results, withdrawals, and adverse events (participants experiencing
any adverse event, or serious adverse event).
Assessment of risk of bias in included studies
We planned to use the Oxford Quality Score as the basis for in-
clusion (Jadad 1996b), limiting inclusion to studies that were ran-
domised and double-blind as a minimum.
Two review authors (SD, RAM) planned to independently as-
sessed risk of bias for each study, using the criteria outlined in the
CochraneHandbook for Systematic Reviews of Interventions (Chapter
8, Higgins 2011), and adapted from those used by the Cochrane
Pregnancy andChildbirthGroup,with any disagreements resolved
by discussion. We assessed the following for each study.
1. Random sequence generation (checking for possible
selection bias). We planned to assess the method used to generate
the allocation sequence as: low risk of bias (any truly random
process: random number table; computer random number
generator); unclear risk of bias (when the method used to
generate the sequence was not clearly stated). We planned to
exclude studies at a high risk of bias that used a nonrandom
process (odd or even date of birth; hospital or clinic record
number).
2. Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
prior to assignment determines whether intervention allocation
could have been foreseen in advance of, or during, recruitment,
or changed after assignment. We planned to assess the methods
as: low risk of bias (telephone or central randomisation;
consecutively numbered, sealed, opaque envelopes); unclear risk
of bias (when the method was not clearly stated). We planned to
exclude studies that did not conceal allocation and were therefore
at a high risk of bias (open list).
3. Blinding of participants and personnel (checking for
possible performance bias), and blinding of outcome assessment
(checking for possible detection bias). We planned to assess the
methods used to blind study participants and outcome assessors
from knowledge of which intervention a participant received.
We planned to assess the methods as: low risk of bias (study
stated that it was blinded and described the method used to
achieve blinding, used identical tablets, matched in appearance
and smell); unclear risk of bias (study stated that it was blinded
but did not provide an adequate description of how it was
achieved). We planned to exclude studies at a high risk of bias
that were not double-blind.
4. Incomplete outcome data (checking for possible attrition
bias due to the amount, nature, and handling of incomplete
outcome data). We assessed the methods used to deal with
incomplete data as: low risk of bias (fewer than 10% of
participants did not complete the study or used ’baseline
observation carried forward’ analysis, or both); unclear risk of
bias (used ’last observation carried forward’ (LOCF) analysis); or
high risk of bias (used ’completer’ analysis).
5. Size of study (checking for possible biases confounded by
small size). We planned to assess studies as being at low risk of
bias (200 participants or more per treatment arm); unclear risk
of bias (50 to 199 participants per treatment arm); or high risk of
bias (fewer than 50 participants per treatment arm).
Measures of treatment effect
We planned to calculate the number needed to treat for an addi-
tional beneficial outcome (NNT) as the reciprocal of the absolute
risk reduction (ARR; McQuay 1998). For unwanted effects, the
number needed to treat becomes the number needed to treat for
an additional harmful outcome (NNH) and is calculated in the
same manner. We planned to use dichotomous data to calculate
risk ratio (RR) with 95% confidence intervals (CI) using a fixed-
effect model unless we found significant statistical heterogeneity
(see Data synthesis). We would not use continuous data in analy-
ses.
Unit of analysis issues
We planned to split the control treatment arm between active
treatment arms in a single study if the active treatment arms were
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not combined for analysis. We did not anticipate that any cross-
over studies would be included, as they are usually of short dura-
tion.
Dealing with missing data
Weplanned to use intention-to-treat (ITT) analysis where the ITT
population consisted of participants who were randomised, took
at least one dose of the assigned study medication, and provided
at least one postbaseline assessment. We planned to assign missing
participants as zero improvement wherever possible.
Assessment of heterogeneity
Weplanned to deal with clinical heterogeneity by combining stud-
ies that examined similar conditions. We planned to assess statis-
tical heterogeneity visually (L’Abbé 1987), and with the use of the
I2 statistic. If the I2 value was greater than 50%, we planned to
consider possible reasons for this.
Assessment of reporting biases
The aim of this reviewwas to use dichotomous outcomes of known
utility and of value to people with neuropathic pain (Hoffman
2010;Moore 2010b;Moore 2010c;Moore 2010d;Moore 2013a).
The review did not depend on what the authors of the original
studies chose to report or not. We would have extracted and used
continuous data, which probably will reflect efficacy and utility
poorly, if useful for illustrative purposes only.
We planned to assess publication bias using a method designed to
detect the amount of unpublished data with a null effect required
to make any result clinically irrelevant (usually taken to mean a
NNT of 10 or higher in this condition; Moore 2008).
Data synthesis
We planned to use a fixed-effect model for meta-analysis. We
would use a random-effects model for meta-analysis if there was
significant clinical heterogeneity and it was considered appropri-
ate to combine studies.
Quality of evidence
We planned to use the GRADE system to assess the quality of the
evidence related to the key outcomes listed in Types of outcome
measures, as appropriate (Appendix 5; Chapter 12,Higgins 2011).
At least two review authors planned to independently rated the
quality of evidence for each outcome. We planned to assess poten-
tial for publication bias, based on the amount of unpublished data
required to make the result clinically irrelevant (Moore 2008).
In addition, there may be circumstances where the overall rating
for a particular outcome needs to be adjusted as recommended by
GRADE guidelines (Guyatt 2013a). For example, if there are so
fewdata that the results are highly susceptible to the randomplay of
chance, or if studies use LOCF imputation in circumstances where
there are substantial differences in adverse event withdrawals, one
would have no confidence in the result, and would need to down-
grade the quality of the evidence by three levels, to very low qual-
ity. In circumstances where there were no data reported for an
outcome, we planned to report the level of evidence as very low
quality (Guyatt 2013b). We would also consider any other factors
while making GRADE assessments.
’Summary of findings’ table
We planned to include a ’Summary of findings’ table as set out
in the Pain, Palliative and Supportive Care Group (PaPaS) author
guide (PaPaS 2012), and recommended in the Cochrane Hand-
book for Systematic Reviews of Interventions, Section 4.6.6 (Higgins
2011). The table would have included outcomes equivalent to
moderate benefit (at least 30% pain intensity reduction or PGIC
much or very much improved, or both) and substantial benefit (at
least 50% pain intensity reduction or PGIC very much improved,
or both), withdrawals due to lack of efficacy, withdrawals due to
adverse events, serious adverse events, and death (a particular se-
rious adverse event).
For the ’Summary of findings’ table we used the following descrip-
tors for levels of evidence (EPOC 2015).
• High: This research provides a very good indication of the
likely effect. The likelihood that the effect will be substantially
different† is low.
• Moderate: This research provides a good indication of the
likely effect. The likelihood that the effect will be substantially
different† is moderate.
• Low: This research provides some indication of the likely
effect. However, the likelihood that it will be substantially
different† is high.
• Very low: This research does not provide a reliable
indication of the likely effect. The likelihood that the effect will
be substantially different† is very high.
† Substantially different: a large enough difference that it might
affect a decision.
Subgroup analysis and investigation of heterogeneity
We planned all analyses to be according to individual painful con-
ditions, because placebo response rates for the same outcome can
vary between conditions, as can the drug-specific effects (Moore
2009).
Possible issues for subgroup analysis might be dose, formulation,
and route of administration. A minimum of two studies and 200
participants were required for any subgroup analysis.
Sensitivity analysis
We planned no sensitivity analysis because the evidence base is
known to be too small to allow reliable analysis.
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R E S U L T S
Description of studies
Results of the search
The searches of CENTRAL, MEDLINE, and Embase identified
1127 records; 1126 of these clearly did not satisfy the inclusion
criteria. We read the full text of the one remaining record for
possible inclusion and excluded it (Palangio 2000). Searches of
clinical trials databases did not identify any relevant ongoing or
unpublished studies (see Figure 1).
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Figure 1. Study flow diagram.
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Included studies
No studies satisfied our inclusion criteria.
Excluded studies
We excluded one study (Palangio 2000). This was a ran-
domised, double-blind comparison of paracetamol plus codeine
with ibuprofen plus hydrocodone over four weeks in 469 partici-
pants with chronic pain. Of these, three participants had diabetic
neuropathy, five had PHN, and 21 had other neurological chronic
pain; most participants had chronic musculoskeletal pain. Results
for these actual and possible neuropathic pain conditions were not
presented separately.
Risk of bias in included studies
We did not assess risk of bias as there were no included studies.
Effects of interventions
See: Summary of findings for the main comparison
Paracetamol alone, paracetamol plus codeine, or paracetamol plus
dihydrocodeine compared with placebo for neuropathic pain
We found no studies satisfying our inclusion criteria.We have only
very low quality evidence and are very uncertain about estimates
of benefit and harm.
D I S C U S S I O N
Summary of main results
We found no RCTs assessing the beneficial or harmful effects
of paracetamol alone, or in combination with codeine or dihy-
drocodeine, in the treatment of any type of neuropathic pain; only
very low quality evidence was available. This is despite paraceta-
mol, alone or in fixed dose combination with codeine or dihy-
drocodeine, being one of the most commonly used first-line treat-
ments for neuropathic pain conditions such as PHN, PDN, neu-
ropathic low back pain, or phantom limb pain (Hall 2013). The
absence of evidence for efficacy probably explains why these treat-
ments do not feature in neuropathic pain guidelines.
Overall completeness and applicability of
evidence
There is no evidence from randomised, double-blind, compara-
tive studies to support or refute the use of paracetamol alone, or
combined with codeine or dihydrocodeine, for the treatment of
neuropathic pain. One excluded study had only a trivial number
of participants with neuropathic pain and did not report on them
separately (Palangio 2000).
During our searches, we found no large body of evidence with
other study designs, such as open comparative studies, or obser-
vational studies, other than one case report of one patient given
intravenous paracetamol (Gulcu 2007).
There are only small amounts of evidence for combinations
of paracetamol with other opioids. For paracetamol combina-
tions with tramadol, we identified a single randomised, double-
blind, placebo-controlled study of modest size (160 participants)
(Freeman 2007), an open randomised study (Ko 2010), and a
cohort study (Danilov 2007), all in the treatment of PDN. We
also found a single observational study of paracetamol plus oxy-
codone (Gatti 2009).While our searches were not designed to find
all studies with paracetamol combined with opioids, the absence
of a significant body of evidence is confirmed by other reviews
(Finnerup 2015).
The main importance is the stark contrast between widespread
use of paracetamol, with or without codeine or dihydrocodeine,
in neuropathic pain, and absence of evidence of efficacy. This is
especially important at a time when the efficacy of paracetamol
in other chronic pain conditions is being challenged. Paracetamol
alone is nobetter thanplacebo for lowback pain (Saragiotto 2016),
spinal pain, or osteoarthritis (Machado 2015), and its use has been
challenged in cancer pain (Mercadante 2013). The assumed safety
of paracetamol is also being challenged (Roberts 2016).
Quality of the evidence
We found no RCTs.
Potential biases in the review process
We know of no potential biases in the review process. It is unlikely
that there is a large body of unpublished evidence showing a large
effect from paracetamol alone or in combination with codeine or
dihydrocodeine in neuropathic pain.
Agreements and disagreements with other
studies or reviews
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We identified no other relevant reviews. A wide-ranging review
of drug therapies for neuropathic pain also found no relevant tri-
als (Finnerup 2015), as did a Cochrane Review on combination
pharmacotherapy (Chaparro 2012).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For people with neuropathic pain
There is insufficient evidence to support or refute the suggestion
that paracetamol, alone or in combination with codeine or dihy-
drocodeine, has any efficacy in any neuropathic pain condition.
For clinicians
There is insufficient evidence to support or refute the suggestion
that paracetamol, alone or in combination with codeine or dihy-
drocodeine, has any efficacy in any neuropathic pain condition.
For policy makers
There is insufficient evidence to support or refute the suggestion
that paracetamol, alone or in combination with codeine or dihy-
drocodeine, has any efficacy in any neuropathic pain condition. It
should be noted that there is evidence of lack of effect of parac-
etamol alone in other chronic pain conditions. In the absence of
any supporting evidence, these drugs should probably not be rec-
ommended, except at the discretion of a pain specialist.
For funders
There is insufficient evidence to support or refute the suggestion
that paracetamol, alone or in combination with codeine or dihy-
drocodeine, has any efficacy in any neuropathic pain condition. It
should be noted that there is evidence of lack of effect of parac-
etamol alone in other chronic pain conditions.
Implications for research
Large, robust randomised trials with patient-centred outcomes
would be required to produce evidence to support or refute effi-
cacy of paracetamol, alone or in combination with codeine or di-
hydrocodeine, in neuropathic pain. The necessary design of such
trials is well established, but, for opioids in neuropathic pain, the
outcomes should be those of at least 30% and at least 50% pain
intensity reduction over baseline at the end of a trial of 12 weeks’
duration in participants continuing on treatment. Withdrawal for
any reason should be regarded as treatment failure, and last obser-
vation carried forward (LOCF) analysis should not be used. This
is because, in chronic pain, opioids frequently produce withdrawal
rates of 50% or more, meaning that LOCF analysis can overstate
treatment efficacy to a large extent.
Given the knowledge that paracetamol is proven to be without
effect or has no evidence to support efficacy in any chronic pain
condition, the value of such trials would be questionable.
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